STAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. I, too, wanted to express how devastated I am over losing our colleague Helen Branswell. She was kind, scrupulous, brilliant, and truly inspiring in action. Thank you, Helen. The need-to-know this morning Privately held U.K. biotech OMass Therapeutics raised $310 million to support the clinical development of a drug to treat congenital adrenal hyperplasia, an inherited endocrine disorder. The investment firm Orbimed raised nearly $3 billion for two, new private equity funds that will invest in U.S, European and Asian health care companies. Investor: China’s biotech boom threatens U.S. venture capital From STAT’s Allison DeAngelis: The rise of Chinese biotech isn’t just impacting U.S. companies, one investor is warning. It’s threatening VC firms. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe